Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.

N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.

PMID:
31914241
2.

Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand.

Cappellini MD, Kattamis A, Viprakasit V, Sutcharitchan P, Pariseau J, Laadem A, Jessent-Ciaravino V, Taher A.

Am J Hematol. 2019 Oct;94(10):E261-E264. doi: 10.1002/ajh.25584. Epub 2019 Aug 13. No abstract available.

3.

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.

Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM.

Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.

4.

Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ).

Taher A, Viprakasit V, Cappellini MD, Sutcharitchan P, Ward R, Mahmoud D, Laadem A, Khan A, Gwaltney C, Harding G, Attie K, Zhang X, Zou J, Pariseau J, Hu XH, Kattamis A.

Am J Hematol. 2019 Feb;94(2):171-176. doi: 10.1002/ajh.25343. Epub 2018 Nov 26.

5.

Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ).

Taher A, Cappellini MD, Viprakasit V, Sutcharitchan P, Mahmoud D, Laadem A, Khan A, Gwaltney C, Harding G, Attie K, Zhang X, Zou J, Pariseau J, Henry Hu X, Kattamis A.

Am J Hematol. 2019 Feb;94(2):177-183. doi: 10.1002/ajh.25344. Epub 2018 Nov 26.

6.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

7.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
8.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A.

Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.

PMID:
28870615
9.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J.

Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9. Epub 2015 Sep 14.

10.

RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1.

Ear J, Huang H, Wilson T, Tehrani Z, Lindgren A, Sung V, Laadem A, Daniel TO, Chopra R, Lin S.

Blood. 2015 Aug 13;126(7):880-90. doi: 10.1182/blood-2015-01-622522. Epub 2015 Jun 24.

PMID:
26109203
11.

Sotatercept in patients with osteolytic lesions of multiple myeloma.

Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E.

Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21.

12.

Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.

Sherman ML, Borgstein NG, Mook L, Wilson D, Yang Y, Chen N, Kumar R, Kim K, Laadem A.

J Clin Pharmacol. 2013 Nov;53(11):1121-30. doi: 10.1002/jcph.160. Epub 2013 Sep 9.

13.

Activin receptor antagonists for cancer-related anemia and bone disease.

Fields SZ, Parshad S, Anne M, Raftopoulos H, Alexander MJ, Sherman ML, Laadem A, Sung V, Terpos E.

Expert Opin Investig Drugs. 2013 Jan;22(1):87-101. doi: 10.1517/13543784.2013.738666. Epub 2012 Nov 6. Review.

PMID:
23127248
14.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A Jr, Laadem A, Seiter K.

J Clin Oncol. 2010 Sep 20;28(27):4207-13. doi: 10.1200/JCO.2009.26.8896. Epub 2010 Aug 16.

15.

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

Lotz JP, Curé H, Janvier M, Asselain B, Morvan F, Legros M, Audhuy B, Biron P, Guillemot M, Goubet J, Laadem A, Cailliot C, Maignan CL, Delozier T, Glaisner S, Maraninchi D, Roché H, Gisselbrecht C.

Eur J Cancer. 2005 Jan;41(1):71-80.

PMID:
15617992
16.

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.

Cals L, Rixe O, François E, Favre R, Merad L, Deplanque G, Laadem A, Juin P, Bereder JM, Bernardini D, Herait P.

Ann Oncol. 2004 Jul;15(7):1018-24.

17.

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.

Misset JL, Vennin P, Chollet PH, Pouillart P, Laplaige PH, Frobert JL, Castera D, Fabro M, Langlois D, Cortesi E, Lucas V, Gamelin E, Laadem A, Otero J.

Ann Oncol. 2001 Oct;12(10):1411-5.

18.

[Oxaliplatin: a first DACH-platinum in oncology].

Laadem A, Cvitkovic E.

Bull Cancer. 2001 Aug;88 Spec No:S9-13. Review. French.

19.

Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer.

Delaloge S, Laadem A, Taamma A, Chouaki N, Cvitkovic E, Pautier P, Misset JL, Lhommé C.

Am J Clin Oncol. 2000 Dec;23(6):569-74.

PMID:
11202798
20.

[Therapeutic intensification and autotransplantation of hematopoietic stem cells in metastatic breast cancers].

Lotz JP, Pène F, Bouleuc C, André T, Macovei C, Laadem A, Debourdeau P, Gumus Y, Merad Z, Avenin D, Esteso A, Bellaiche A, Izrael V.

Presse Med. 1996 Nov 16;25(35):1737-43. Review. French.

PMID:
8977588
21.

[High-dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors].

Lotz JP, Pene F, Bouleuc C, André T, Gligorov J, Avenin D, Esteso A, Bellaiche A, Macovei C, Merad Z, Laadem A, Vanica R, Izrael V.

Contracept Fertil Sex. 1996 Apr;24(4):307-18. Review. French.

PMID:
8704806

Supplemental Content

Loading ...
Support Center